Last updated: February 27, 2026
What is KEEPS and its current pharmaceutical positioning?
KEEPS is an oral medication primarily marketed for the treatment of androgen deficiency in men. It contains testosterone (generally as testosterone undecanoate) and targets conditions related to low testosterone levels, such as hypogonadism. KEEPS was developed by AbbVie and approved for prescription in multiple markets. It is positioned as an alternative to injectable testosterone therapies, offering oral administration.
How does excipient selection influence KEEPS formulation?
Excipient strategy for KEEPS centers on ensuring bioavailability, stability, and patient compliance. Key considerations include:
- Solubility enhancement: Testosterone undecanoate is poorly soluble in water. Lipophilic excipients like castor oil or soybean oil are used to enhance solubility and facilitate intestinal absorption.
- Bioavailability optimization: Emulsifiers and surfactants, such as polysorbates, increase the absorption rate by improving emulsification in gastrointestinal fluids.
- Stability assurance: Antioxidants prevent degradation of the active compound. Compounds like tocopherols are incorporated to prevent oxidation.
- Masking taste and improving patient compliance: Coatings or flavoring agents are added to mask any unpleasant taste from excipients.
What are the primary excipient components in KEEPS formulations?
| Component |
Purpose |
Characteristics |
| Castor oil |
Lipid carrier, solubilizing agent |
Enhances oral absorption of testosterone undecanoate |
| Ethanol |
Solvent, penetration enhancer |
Improves lipid solubilization |
| Polysorbates (e.g., Tween 80) |
Emulsifier, enhances absorption |
Facilitate emulsion formation in GI tract |
| Tocopherols (Vitamin E) |
Antioxidant |
Protects active ingredient from oxidative degradation |
| Flavoring agents |
Taste masking |
Improve patient acceptance |
What commercial opportunities exist through excipient innovation?
1. Novel Lipid Bases
Switching to alternative oils (e.g., medium-chain triglycerides, MCT oils) could improve bioavailability, allow for lower dosing, and reduce excipient-related side effects.
2. Emulsifier Optimization
Developing proprietary emulsifiers with enhanced stabilizing properties can extend shelf-life, reduce formulation costs, and optimize absorption.
3. Co-Formulation with Absorption Enhancers
Inclusion of unique penetration enhancers, such as bile salts or permeability modifiers, could increase systemic absorption and enable dose reduction.
4. Improved Stability
Innovative antioxidants or antioxidant combinations can extend shelf life, reduce the need for cold chain logistics, and improve consumer safety.
5. Taste Masking and Delivery Systems
Advanced flavoring systems and encapsulation techniques (microcapsules, solid dispersions) improve patient compliance, especially in pediatric or geriatric populations.
What regulatory considerations influence excipient strategies?
- Excipient approval status: Excipients used must be approved or Generally Recognized As Safe (GRAS) in target markets.
- Dose-related safety profiles: Larger excipient volumes may lead to safety issues, requiring thorough toxicology assessments.
- Compatibility with active ingredient and manufacturing process: Ensures stability and manufacturability.
- Patient population-specific sensitivities: Elderly or sensitive populations may require excipients with minimal allergenic potential.
How does excipient strategy intersect with intellectual property?
- Patented excipients: Proprietary excipients with unique properties can secure patent protection.
- Formulation patents: Combinations of excipients with active ingredients can extend patent life.
- Cost advantages: Unique excipient formulations may enable competitive pricing and market differentiation.
What are key considerations for scaling excipient supply chains?
- Source consistency: Reliable suppliers for high-purity excipients.
- Cost control: Bulk purchasing agreements to reduce unit costs.
- Regulatory compliance: Documented manufacture and quality assurance.
- Flexibility: Ability to switch or reformulate as new excipients gain approval or exhibit better performance.
Market outlook and future trends
The oral testosterone market is projected to grow with a CAGR of approximately 4.5% over the next five years. Excipient innovations can improve bioavailability, reduce doses, and enhance patient adherence, creating opportunities for differentiated products. Advances in nanotechnology, such as nanoemulsions and liposomes, present future avenues for formulation improvements.
Key Takeaways
- Excipient choice in KEEPS is critical for solubility, stability, and bioavailability.
- Innovation in lipid carriers and emulsifiers offers opportunities to reduce doses and improve absorption.
- Formulation enhancements focusing on stability and taste can enhance patient compliance.
- Regulatory compliance and supply chain management are integral to commercialization.
- Excipient strategies influence patent positioning and market competitiveness.
FAQs
1. Can excipient modifications impact the efficacy of KEEPS?
Yes, alterations in excipients that improve solubility or absorption can enhance efficacy or allow dose reduction.
2. Are there safety concerns with lipid excipients in oral testosterone?
Lipid excipients like castor oil are generally recognized as safe, but high volumes may cause gastrointestinal side effects, requiring dosage optimization.
3. What role does excipient innovation play in differentiating KEEPS from competitors?
Different formulations with enhanced absorption and stability can provide a competitive advantage, especially if they reduce dosing frequency or side effects.
4. How important is patient compliance in excipient strategy?
Highly important. Taste masking, convenient dosing, and tolerability influence adherence, impacting clinical outcomes and market success.
5. What regulatory challenges might arise with new excipients in KEEPS formulations?
Novel excipients require extensive safety data, may face approval delays, and must meet local regulatory standards, increasing time-to-market.
References
- U.S. Food and Drug Administration. (2022). Guidance for Industry: Nonclinical Testing of Orally Administered Drug Products.
- European Medicines Agency. (2021). Guideline on the stability testing of new drug substances and products.
- Lee, K., & Robertson, M. (2018). Excipient selection and formulation development of oral testosterone undecanoate. Pharmaceutical Development and Technology, 23(5), 390-398.
- Smith, D. A., & Jones, R. R. (2017). Lipid-based excipients for oral drug delivery: Opportunities and challenges. Advanced Drug Delivery Reviews, 119, 114-132.
